Analysts’ Updated EPS Estimates for February, 13th (ALV, ARAY, CHGG, CYTX, DO, GHDX, HAB, HOLX, INGN, JACK)

Analysts’ updated eps estimates for Tuesday, February 13th:

Allianz (FRA:ALV) had its neutral rating reiterated by analysts at Barclays PLC.

Accuray (NASDAQ:ARAY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $5.75 price target on the stock. According to Zacks, “Over the past six months, Accuray has outperformed the broader industry. Additionally, the company reported impressive second quarter of fiscal 2018 results. Also, the company reiterated its guidance for fiscal 2018. Accuray rides on the market’s solid response to the Radixact platform. Growing adoption of non-surgical treatment options, successful execution of restructuring plans and accretive acquisitions are other positives. Accuray’s significant international presence helps broaden its customer base. On the flip side, long sales and implementation cycles of the CyberKnife and TomoTherapy systems is a headwind. Fluctuations in currency exchange rates will continue to adversely impact Accuray’s backlog. Furthermore, unfavorable product mix, declining service revenues, sluggish macro-economic conditions and pricing headwinds are major concerns.”

Chegg (NYSE:CHGG) had its outperform rating reissued by analysts at Barrington Research. They currently have a $22.00 target price on the stock, up from their previous target price of $19.00.

Cytori Therapeutics (NASDAQ:CYTX) was given a $4.00 price target by analysts at Maxim Group. The firm currently has a buy rating on the stock.

Diamond Offshore Drilling (NYSE:DO) was given a $13.00 price target by analysts at B. Riley. The firm currently has a hold rating on the stock.

Genomic Health (NASDAQ:GHDX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Genomic Health's sole reliance on the Breast Oncotype DX test is a concern. Moreover,  the company’s rising operating expenses also pose challenges. However, over the past three months, Genomic Health has been trading above the broader industry. We are encouraged by the company witnessing a  year-over-year rise in revenues, driven by solid performances in United States and internationally. Within prostate cancer, the Oncotype DX Genomic Prostate Score test received positive Local Coverage Determination to expand Medicare coverage by Palmetto GBA. The company also made positive developments for its Oncotype DX Breast Recurrence Score tests. Also, it established private coverage for the test in Germany.”

Hamborner Reit (ETR:HAB) was given a €9.80 ($12.10) target price by analysts at National Bank Financial. The firm currently has a neutral rating on the stock.

Hologic (NASDAQ:HOLX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $43.00 target price on the stock. According to Zacks, “Hologic posted better-than-expected results in first-quarter fiscal 2018 primarily on strength in the Molecular Diagnostics. Growth across all geographical regions buoys optimism. Breast Health performed well based on differentiated products. We are upbeat about the recent CE Mark approval for Brevera breast biopsy system. Also, the PMA approval for the Aptima HBV Quant Assay for quantitation of hepatitis B viral load on the fully automated Panther system buoys optimism. Hologic’s strong cash position is encouraging. On the flip side, the blood screening divestiture continues to impede growth. Foreign currency headwinds and a competitive landscape also continue to pose challenges for the company. Over the past three months, Hologic has been trading below the broader industry.”

Inogen (NASDAQ:INGN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $131.00 target price on the stock. According to Zacks, “Over the last year, Inogen has outperformed the broader industry in terms of price. The company expects direct-to-consumer sales to be its fastest growing channel, followed by domestic business-to-business sales in the coming quarters, with solid focus in Europe. The company is also upbeat about its full-year 2017 revenue guidance. Solid domestic and international business-to-business sales has been boosting Inogen. The company took a series of strategic initiatives to strengthen its product offerings and market position. On the flip side, declining rental revenues raise concern. Moreover, since the company generates a significant portion of its revenues from the international market, volatile foreign exchange rate will continue to raise concern. Low POC adoption, intensifying competition, reimbursement cuts and foreign exchange headwinds are other major concerns. Reimbursement cuts and foreign exchange headwinds are other major concerns.”

Jack in the Box (NASDAQ:JACK) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Jack in the Box’s premium and value offerings, focus on menu innovation, franchising and delivery are expected boost sales, going forward. However, the company’s limited international presence is a disadvantage and could hurt its competitive position. Comps at Qdoba brand had suffered due to poor restaurant level execution. A soft industry backdrop continues to hurt sales too. Pre-opening costs, promotional activity and labor expenses have also been weighing on margins. Further, increased competition in breakfast and lunch day parts remain concerns. Jack in the Box’s shares underperformed the industry in the past year. Estimates too have moved down ahead of the fiscal fourth-quarter earnings release.”

Kadmon (NYSE:KDMN) had its positive rating reiterated by analysts at Piper Jaffray Companies. Piper Jaffray Companies currently has a $9.00 price target on the stock, up from their previous price target of $7.00.

Munchener Ruckvers (AMS:MEURV) had its buy rating reiterated by analysts at Barclays PLC.

Aurubis (ETR:NDA) had its neutral rating reiterated by analysts at DZ Bank AG.

NVR (NYSE:NVR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $3,218.00 target price on the stock. According to Zacks, “NVR exhibited mixed performances in fourth-quarter 2017 wherein earnings missed the Zacks Consensus Estimate by 11.3% and decreased 24% from the year-ago level. However, total revenues (Homebuilding & Mortgage Banking fees) increased 3.7% year over year, on account of higher housing revenues (up 21%). New orders, settlements and backlog of homes also climbed 18%, 5% and 23.9%, respectively, in the quarter. Gross margin expanded 150 basis points on a modest improvement in pricing along with moderating construction costs. Meanwhile, NVR's shares have outperformed its industry in the past year. Estimates for 2018 has also moved up significantly over the last 60 days, reflecting analysts’ optimism surrounding the stock.”

RWE (FRA:RWE) was given a €20.10 ($24.81) target price by analysts at Morgan Stanley. The firm currently has a neutral rating on the stock.

Rayonier (NYSE:RYN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $36.00 target price on the stock. According to Zacks, “Shares of Rayonier have outperformed the industry it belongs to in the past three months. Moreover, the stock has seen the Zacks Consensus Estimate for 2018 earnings being revised upward in a week’s time. Notably, the company’s fourth-quarter 2017 results benefited from strong performance of its three timber segments. Rayonier’s portfolio of timberlands reflects geographical diversity. Moreover, the company is likely to benefit from the developments in biogenetics & cloning that help in fast growth of trees. The company has also upgraded its U.S. South portfolio through strategic acquisitions and is expected to gain from the recovery in the country’s housing sector. Such efforts position the company for long-term growth. However, the company faces competition from its substitutes and other market players in the timberland sector. Foreign exchange fluctuations add to its woes.”

Spectrum Brands (NYSE:SPB) was given a $125.00 target price by analysts at BMO Capital Markets. The firm currently has a buy rating on the stock.

Teva Pharmaceutical Industries (NYSE:TEVA) had its sell rating reissued by analysts at Wells Fargo & Co.

United Continental (NYSE:UAL) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $72.00 price target on the stock. According to Zacks, “Shares of United Continental have outperformed its industry in the last three months. The stock rallied 12.1% against the industry's gain of 8.1% in the period. Ushering in further good news, the company reported better-than-expected earnings and revenues in the fourth quarter of 2017. The top line also increased substantillay year over year. Strong demand for air travel aided the top line. We are also impressed by the company's efforts to reward its shareholders. The company has repurchased stock worth $553 million in the final quarter of 2017. The company's effoorts to expand operations are a further positive. However, high costs hurt the company's bottom line in the fourth quarter. We are also concerned about capacity overexpansion woes at United Continental. “

Unisys (NYSE:UIS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Unisys reported strong fourth-quarter 2017 results with healthy year-over-year increase in revenues and earnings. The company has been restructuring its business to improve profitability. It has a strong product line in its Technology segment and is expanding distribution capabilities by building new reseller channels. The company’s sustained investments in strategic high-potential products and services are expected to drive growth and boost results. The company has outperformed the industry in the last three months. However, Unisys faces stiff competition in the information services and technology marketplace. Also, it operates in a highly volatile industry characterized by rapid technological innovation and continually changing customer demand patterns. A significant amount of Unisys’ revenues comes from the international operations, exposing it to the impact of adverse currency movements.”

Viacom (NASDAQ:VIAB) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $37.00 price target on the stock. According to Zacks, “Shares of Viacom have outperformed its industry in the past three months. Ushering in further good news, the company reported better-than-expected earnings per share in the first quarter of fiscal 2018. Results were aided by the company's strong performance on the international front. International revenues increased 18% and 6% at its two units — Media Networks and Filmed Entertainment, respectively.  We are also impressed by Viacom's efforts to revive its fortunes. Moreover, if the merger between Viacom and CBS materialize then the deal might benefit the former with cost synergies, among other factors. However, we remain concerned about the decline in domestic affiliate revenues due to the loss of subscribers. For 2018, the company expects domestic affiliate revenues to decline at the low end of mid-single-digits. Declining domestic advertisement revenues raise concerns as well.”

Varonis Systems (NASDAQ:VRNS) had its outperform rating reaffirmed by analysts at Imperial Capital. They currently have a $63.00 price target on the stock, up from their previous price target of $52.00.

Receive News & Ratings for Allianz SE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allianz SE and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply